Nautilus Biotechnology (NAUT) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
28 Apr, 2026Executive summary
Annual meeting scheduled for June 17, 2026, with virtual attendance available for shareholders.
Shareholders are encouraged to review proxy materials and vote by June 16, 2026.
Voting matters and shareholder proposals
Election of two Class II directors: Parag Mallick and Farzad Nazem, with board recommendation to vote in favor.
Ratification of PricewaterhouseCoopers LLP as independent auditor for the year ending December 31, 2026.
Advisory vote on executive compensation for the fiscal year ended December 31, 2025.
Advisory vote on the frequency of future say-on-pay votes, with board recommending annual votes.
Proxyholders may vote on other business arising at the meeting or any adjournment.
Board of directors and corporate governance
Board recommends the election of two director nominees for Class II positions.
Latest events from Nautilus Biotechnology
- Board recommends all proposals, annual say-on-pay, and highlights strong governance and compliance.NAUT
Proxy filing28 Apr 2026 - Operating expenses fell 14% and net loss narrowed as commercialization and early access expanded.NAUT
Q1 202628 Apr 2026 - Nautilus is launching a disruptive proteomics platform targeting major drug development challenges.NAUT
Investor Summit Virtual Conference25 Mar 2026 - New proteomics platform promises comprehensive, reproducible protein analysis with broad applications.NAUT
TD Cowen 46th Annual Health Care Conference2 Mar 2026 - Operating expenses and net loss declined, with commercial launch and revenue ramp set for 2027.NAUT
Q4 202526 Feb 2026 - Q2 net loss reached $18M as platform development advanced and 2025 launch remained on track.NAUT
Q2 20242 Feb 2026 - 2025 launch targets deep, accessible proteomics with strong market and customer momentum.NAUT
Goldman Sachs 45th Annual Global Healthcare Conference1 Feb 2026 - Comprehensive, high-sensitivity proteomics platform targets 2025 launch with robust financials.NAUT
Morgan Stanley 22nd Annual Global Healthcare Conference22 Jan 2026 - Q3 net loss was $16.4M; platform launch set for late 2025; cash totals $221.2M.NAUT
Q3 202418 Jan 2026